---
acquisition_date: '2025-10-21T16:20:55.280130'
acquisition_method: paperscraper_automated
audience:
- professional
- researcher
authors: '[''GiuseppeCecere'', ''Theresa MBallard'', ''FredericKnoflach'', ''MichaelHoner'',
  ''Joerg FHipp'', ''PilarGarces'', ''ThomasMueggler'', ''BasilKünnecke'', ''AndreasBruns'',
  ''Eric PPrinssen'', ''PhilippSchoenenberger'', ''PhilippJanz'', ''RogerRedondo'',
  ''BarbaraBiemans'', ''HennerKnust'', ''AndrésOlivares-Morales'', ''AlessandroBrigo'',
  ''Jan MichaelSchulz'', ''DanielBertrand'', ''MichaelSaxe'', "Eoin CO''Connor", ''Maria-ClemenciaHernandez'']'
conditions:
- tourette_syndrome
- asd
content_type: research_paper
doi: 10.3389/fphar.2025.1626078
journal: Frontiers in pharmacology
keywords:
- tourette_syndrome
- asd
- glutamate_gaba
- neurochemistry
- pubmed
patient_friendly: false
primary_category: neurochemistry/glutamate-gaba
publication_date: '2025-08-05'
reading_level: academic
search_priority: standard
search_query: GABA neurodevelopmental
search_tags:
- tourette_syndrome
- asd
- glutamate_gaba
- neurochemistry
- pubmed
- research
- academic
source: PUBMED via Paperscraper
title: 'Preclinical pharmacology of alogabat: a novel GABA'
topics:
- tourette_syndrome
- asd
- glutamate_gaba
type: research_paper
---

# Preclinical pharmacology of alogabat: a novel GABA

**Authors:** ['GiuseppeCecere', 'Theresa MBallard', 'FredericKnoflach', 'MichaelHoner', 'Joerg FHipp', 'PilarGarces', 'ThomasMueggler', 'BasilKünnecke', 'AndreasBruns', 'Eric PPrinssen', 'PhilippSchoenenberger', 'PhilippJanz', 'RogerRedondo', 'BarbaraBiemans', 'HennerKnust', 'AndrésOlivares-Morales', 'AlessandroBrigo', 'Jan MichaelSchulz', 'DanielBertrand', 'MichaelSaxe', "Eoin CO'Connor", 'Maria-ClemenciaHernandez']

**Journal:** Frontiers in pharmacology

**Publication Date:** 2025-08-05

**DOI:** 10.3389/fphar.2025.1626078

## Abstract

Alterations in the GABAergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (ASD) and Angelman syndrome (AS), particularly in cases involving large deletions in the 15q11-13 region. Positive modulation of GABA Alogabat was assessed for binding and functional activity at GABA Alogabat is a potent positive allosteric modulator of GABA Alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.

---

## Research Details

**Source:** PUBMED
**Category:** neurochemistry
**Primary Topics:** tourette_syndrome, asd, glutamate_gaba
**Search Query:** GABA neurodevelopmental
**Acquisition Date:** 2025-10-21

*This paper was automatically acquired and processed for the neurodevelopmental disorders knowledge base.*
